Drug Safety Monitoring Category Procurement Intelligence Report 2026-2030

Drug safety monitoring represents the systematic framework through which pharmaceutical companies, regulatory agencies, and contract research organizations track and evaluate medication safety from clinical development through post-market surveillance. The market comprises software platforms, outsourced safety services, consulting, and data analytics solutions designed to identify adverse events, manage risk, and ensure regulatory compliance. Growth has been consistent as the global pharmaceutical industry expands its pipeline and regulatory bodies maintain increasingly rigorous pharmacovigilance standards.

• •Market size estimated at approximately $9.64 billion in 2025 with projections to exceed $10.8 billion by 2028
• •Services and software segments both contributing significantly to overall market revenue
• •Post-market surveillance represents an increasing share of total pharmacovigilance activity

Stringent regulatory mandates from agencies such as the U.S. Food and Drug Administration, European Medicines Agency, and other global health authorities continue to expand the scope and frequency of safety reporting requirements for drug manufacturers. The rising number of approved biologics, biosimilars, and specialty medications has created greater complexity in safety monitoring, requiring more sophisticated data management and analysis capabilities. Additionally, the global expansion of clinical trials into emerging markets has increased the volume and diversity of safety data that must be collected and processed.

• •Increased regulatory pressure on pharmaceutical companies to maintain robust pharmacovigilance systems
• •Growth in biologics and specialty drug approvals requiring enhanced safety monitoring protocols
• •Rising volume of adverse event reports driving demand for automated processing solutions

The market is typically segmented into software solutions and outsourced services, with the services segment commanding the larger share due to pharmaceutical companies increasingly relying on contract research organizations for safety operations. Geographically, North America dominates the market due to its large pharmaceutical industry and the presence of stringent FDA reporting requirements, followed by Europe and the Asia-Pacific region. Emerging markets in Asia-Pacific are experiencing the fastest growth as regional regulatory frameworks mature and pharmaceutical manufacturing expands.

• •North America holds the largest market share, followed by Europe and Asia-Pacific
• •Services outsourcing represents a substantial and growing portion of market revenue
• •Asia-Pacific region showing accelerated growth due to expanding clinical trial activity and regulatory harmonization

What are the recent trends and outlook?

Artificial intelligence and machine learning are increasingly being integrated into pharmacovigilance operations to automate signal detection, reduce processing time, and improve the accuracy of adverse event identification from diverse data sources including social media and electronic health records. Real-world evidence and data from digital health applications are emerging as important sources for ongoing safety monitoring, prompting vendors to expand their data ingestion and analytics capabilities. The market is expected to maintain its growth trajectory as regulatory pressure continues and the volume of safety data generated by global drug development and commercialization activities expands.

• •AI-powered signal detection and automated case processing becoming standard offerings
• •Integration of real-world evidence and patient-generated health data into safety workflows
• •Long-term forecasts suggest market could approach twenty-four billion dollars by 2035 according to some industry projections